Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475369 · ClinicalTrials.gov registry record · Phase 4
Pancreatic Enzyme Supplementation for Celiac Disease
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02475369 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT02475369, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this protocol is to conduct a pilot study to investigate whether pancreatic enzyme supplementation will improve symptoms in individuals with celiac disease who suffer persistent symptoms despite a gluten free diet. This protocol specifically aims to: 1. Evaluate the efficacy of pancreatic enzyme supplementation for reduction of gastrointestinal symptoms in patients with celiac disease on a gluten free diet. 2. Assess the ability of fecal elastase levels to predict response to pancreatic enzyme supplementation in patients with celiac disease on a gluten free diet.
Interventions
- DRUG pancrelipase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475369
The ClinicalTrials.gov registry entry for NCT02475369 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pancrelipase is the first listed.
NCT02475369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475369 about?
NCT02475369 is a clinical study titled "Pancreatic Enzyme Supplementation for Celiac Disease". The purpose of this protocol is to conduct a pilot study to investigate whether pancreatic enzyme supplementation will improve symptoms in individuals with celiac disease who suffer persistent symptoms despite a gluten free diet. This protocol specifically aims to: 1. Evaluate the efficacy of pancr...
What is the current status of trial NCT02475369?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2015-05. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02475369?
The interventions under investigation include: pancrelipase (DRUG).
Who is sponsoring clinical trial NCT02475369?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.